Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Vermont Tech Scene.
Press releases published on May 31, 2025
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
GlobeNewswire
·
May 31, 2025
Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1 months vs 7.2 months; log-rank p=0.01) in previously untreated patients with metastatic pancreatic ductal …
Trade 350 App: This Trade 350 App Sets New Standard in AI-Driven Trading with Unmatched Security and User Approval
GlobeNewswire
·
May 31, 2025
New York City, NY, May 31, 2025 (GLOBE NEWSWIRE) -- Introduction In the crowded world of online trading platforms, separating legitimate services from elaborate scams can be a daunting task. Trade 350 App has emerged as one of the buzziest names in 2025, …
Starscope: Does Starscope Monocular Really Work for Stargazing & Hiking? Read Full Starscope Monocular Telescope Consumer Report!
GlobeNewswire
·
May 31, 2025
San Diego, CA, May 31, 2025 (GLOBE NEWSWIRE) -- Introduction: Why the Starscope Monocular Is Gaining Popularity in 2025 Whether you're a nature lover, hiker, hunter, or stargazer, having the right optical gear can make or break your outdoor experience. In …
JAMining Expands FCA-Regulated Cloud Mining Services Amid Surging Crypto Market Activity
GlobeNewswire
·
May 31, 2025
Image by JAMining LONDON, May 31, 2025 (GLOBE NEWSWIRE) -- JAMining, a UK-based cloud mining provider regulated by the Financial Conduct Authority (FCA), has announced a major expansion of its services. This strategic move comes amid a surge in global …
PAIRMiner Makes Bitcoin Mining More Accessible Amid Market Surge
GlobeNewswire
·
May 31, 2025
Image by PAIRMiner STUTTGART, Germany, May 31, 2025 (GLOBE NEWSWIRE) -- As Bitcoin prices rise past key resistance levels, investor interest in digital assets is once again on the upswing. PAIRMiner, a cloud-based cryptocurrency mining platform, is helping …
Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
GlobeNewswire
·
May 31, 2025
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001) Libtayo also demonstrated 80% and 65% reductions in the risk of locoregional and distant recurrence, respectively, compared to …
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
GlobeNewswire
·
May 31, 2025
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutation Vepdegestrant was …
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
GlobeNewswire
·
May 31, 2025
Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma1 Post-hoc analysis of NAPOLI 3 study determined characteristics associated with long-term survival, with median …
Une analyse « Late Breaking » démontre les caractéristiques associées à la survie globale à long terme des patients avec un adénocarcinome pancréatique métastatique traités par Onivyde®
GlobeNewswire
·
May 31, 2025
L’essai de Phase III NAPOLI 3 est la plus grande étude interventionnelle réalisée à ce jour avec la plus longue période de suivi des patients avec un adénocarcinome pancréatique métastatique1. L’analyse post-hoc de l’étude NAPOLI 3 a permis de déterminer …
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
GlobeNewswire
·
May 31, 2025
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing deep and durable objective responses up to >2.5 years …
ImPact Biotech Presents Interim Analysis from Phase 3 ENLIGHTED Study of Padeliporfin VTP in LG UTUC at ASCO 2025
GlobeNewswire
·
May 31, 2025
– Complete response (CR) observed in 73% (27/37) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) – – Padeliporfin VTP treatment continues to be safe and well-tolerated, …
Harbinger Health Showcases Multi-Cancer Early Detection Performance in High-Risk Populations at ASCO 2025
GlobeNewswire
·
May 31, 2025
Reflex blood-based multi-cancer early detection (MCED) test demonstrated clinically meaningful per-cancer Positive Predictive Value (PPV) and early-stage sensitivity for multiple cancers with elevated incidence and mortality in a high-risk population Data …
Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
GlobeNewswire
·
May 31, 2025
26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver metastases Deep and durable responses ongoing for up to 37 weeks through the data cutoff, …
Online Crypto Casinos: All iGaming Reveals the Top Sites for Crypto Gamblers in 2025
GlobeNewswire
·
May 31, 2025
Jersey City, NJ, May 31, 2025 (GLOBE NEWSWIRE) -- - These days, the internet is flooded with crypto casinos all claiming to offer the best games, biggest bonuses, and fastest payouts. But finding a truly reputable crypto casino isn’t about luck- it’s …
Free Psychic Medium Readings | Chat with Real Mediums Online – Special 2025 Announcement
GlobeNewswire
·
May 31, 2025
San Francisco, CA, May 31, 2025 (GLOBE NEWSWIRE) -- - In today's digital age, connecting with a psychic medium is easier and more accessible than ever. Whether you're seeking comfort after a loss, clarity on life’s deeper questions, or simply curious about …
PAIRMiner Launches $150 Cloud Mining Incentive as Institutional Bitcoin Holdings Reach Historic Levels
GlobeNewswire
·
May 31, 2025
Amid a surge in institutional Bitcoin investments, PAIRMiner introduces a free cloud mining offer to make crypto access easier for everyday users. Image by PAIRMiner LOS ANGELES, May 31, 2025 (GLOBE NEWSWIRE) -- Cloud mining platform PAIRMiner today …
Snail Inc. 旗下独立品牌 Wandering Wizard 与拉丁美洲工作室 Seven Leaf Clover 达成发行合作，加速全球市场布局
GlobeNewswire
·
May 31, 2025
加利福尼亚州卡尔弗城, May 31, 2025 (GLOBE NEWSWIRE) -- 全球领先的互动数字娱乐领域独立开发商与发行商 Snail, Inc. (Nasdaq: SNAL，以下简称 “Snail Games” 或 “公司”) 宣布，其独立游戏发行品牌 Wandering Wizard 已与阿根廷开发商 Seven Leaf Clover 达成发行合作协议，获得高强度第一人称单人射击游戏 (FPS) Rebel Engine 的发行权。 Rebel Engine 预计将于 2025 年登陆 …
Snail Inc. 旗下獨立品牌 Wandering Wizard 與拉丁美洲工作室 Seven Leaf Clover 建立發行合作夥伴關係，擴大在全球市場的影響力
GlobeNewswire
·
May 31, 2025
加利福尼亞州卡爾弗城, May 31, 2025 (GLOBE NEWSWIRE) -- 全球領先的互動數碼娛樂獨立開發商及發行商 Snail, Inc. (Nasdaq: SNAL)（「Snail Games」或「公司」）宣布其獨立發行品牌 Wandering Wizard，與來自阿根廷的開發商 Seven Leaf Clover 建立發行合作夥伴關係，以獲取極具影響力、單人第一人稱射擊（「FPS」）遊戲 《Rebel Engine》 的發行權利。 遊戲預計將於 2025 年在 PC …
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
GlobeNewswire
·
May 31, 2025
More than half of residents with tardive dyskinesia (TD) residing in long-term care (LTC) settings do not receive standard of care treatment, and one-quarter are left untreated LTC residents are often given a broader diagnosis of extrapyramidal syndrome, …
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS…
GlobeNewswire
·
May 31, 2025
Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits versus second-generation daily oral options Latest Phase 3 SOLARIS data show no …